Patents Assigned to Saliogen Therapeutics, Inc.
  • Transposition-based therapies
    Patent number: 11993784
    Abstract: Gene therapy compositions and methods are provided that make use of novel transposases and/or chimeric transposases for targeted transposition.
    Type: Grant
    Filed: March 29, 2023
    Date of Patent: May 28, 2024
    Assignee: Saliogen Therapeutics, Inc.
    Inventors: Joseph J. Higgins, Scott McMillan, Ray Tabibiazar
  • Transposition-based therapies
    Patent number: 11542528
    Abstract: Gene therapy compositions and methods are provided that make use of transposases and/or chimeric transposases for targeted transposition, including engineered enzymes and nucleic acids encoding the same. The provided compositions and methods are suitable of treating, for example, an inherited or acquired disease in a patient, as well as treating and/or mitigating a variety of diseases.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: January 3, 2023
    Assignee: Saliogen Therapeutics, Inc.
    Inventors: Joseph J. Higgins, Scott McMillan, Ray Tabibiazar